OBJECTIVES The aim of this study was to assess temporal trends and factors associated with digoxin use at discharge among patients admitted with heart failure (HF).
H eart failure (HF) accounts for approximately 1 million admissions as a primary diagnosis each year in the United States (1) . Moreover, the readmission rate approaches almost 30% at 90 days (2) . Therefore, currently, there is a major focus on reducing HF hospital readmission. The Digitalis Investigator Group (DIG), a large randomized, placebo-controlled trial in patients with HF, showed that digoxin significantly reduced hospitalizations for HF, but it also had no impact on all-cause or cardiovascular mortality (3) . Moreover, the DIG pre-specified high-risk subgroup analysis demonstrated that at a 2-year follow up, there was a reduction in all-cause mortality or hospitalization and HF-related mortality for patients with New York Heart Association functional class III/IV symptoms, with left ventricular ejection fractions <25%, and with a cardiothoracic ratio >55%
on chest x-rays (4) We also performed an analysis in which in-hospital deaths were not excluded and rates of in-hospital deaths were analyzed among HFrEF patients with or without digoxin use on admission. status, it was imputed to "no," because we assumed the field was not filled out when none was applied.
FIGURE 1 Flowchart of Study Population
AHA GWTG-HF ¼ American Heart Association Get With The Guidelines-Heart Failure;
HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction.
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Trends of Digoxin Use in Heart Failure given influenza vaccine, or given a pneumococcal vaccine compared with patients discharged on digoxin. Table 3 lists the independent patient and hospital characteristics associated with digoxin prescription. After adjustment, digoxin at discharge was Continued on the next page JACC: HEART FAILURE VOL. 4, NO. 5, 2016 Patel Among patients with HFpEF, use of digoxin at hospital discharge was 9.5% and significantly less than that compared with patients with HFrEF (p < 0.0001).
Characteristics of HFpEF patients with and without digoxin use at discharge are shown in Online Table 4 . Values are mean AE SD, %, or median (range).
Use of digoxin in patients with
ACEI ¼ angiotensin-converting enzyme inhibitor; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CCB ¼ calcium channel blocker; COPD ¼ chronic obstructive pulmonary disease; CRT-D ¼ cardiac resynchronization therapy-defibrillator; CRT-P ¼ cardiac resynchronization therapy-pacemaker; CVA/TIA ¼ cerebrovascular disease/transient ischemic attack; HFrEF ¼ heart failure with reduced ejection fraction; ICD ¼ implantable cardioverter defibrillator; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; UTD ¼ unable to determine. Patel et al.
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Trends of Digoxin Use in Heart Failure The DIG trial was a large randomized clinical trial with 6,800 study participants with systolic HF in sinus rhythm that evaluated the effect of digoxin versus placebo in an outpatient setting using hard clinical endpoints (3) . The study demonstrated a statistically significant reduction in incidence of hospitalization for HF with digoxin, but it did not show any difference in mortality (3). It is noteworthy that the DIG trial was conducted before beta-blockers were proved to reduce mortality and morbidity in HF. However, most patients enrolled in outcome trials of beta-blockers received digoxin. Moreover, small, randomized, placebo- 
<0.0001
Values are n (%). HFrEF ¼ heart failure with reduced ejection fraction.
JACC: HEART FAILURE VOL. 4, NO. 5, 2016 Patel et al. showed that exercise performance decreased when digoxin was withdrawn, whether the patients were on angiotensin-converting enzyme inhibitors or not (13) .
In addition, a meta-analysis that evaluated the use of digoxin in 13 randomized clinical trials in subjects with systolic HF in sinus rhythm showed no effect on longterm mortality, but these trials again demonstrated a significant reduction in clinical symptoms and incidence of hospitalizations (14) . A more modern but retrospective observational study demonstrated a decrease in re-admission in subjects with decompensated systolic HF when they were discharged with a prescription for digoxin (15) . ucla.edu. Trends of Digoxin Use in Heart Failure 355
